Clinical Trial Update: Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 extension trial assessing safety and efficacy of risankizumab (BI 655066/ABBV-066) in moderate to severe chronic plaque psoriasis has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2019-11-08